Medifast (MED) Capital Expenditures (2010 - 2026)

Medifast (MED) has 17 years of Capital Expenditures data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 27.99% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 27.29% YoY), and the FY2025 full-year result was $5.6 million, down 24.68% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.1 million, down from $1.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $9.1 million in Q4 2022 and bottomed at $946000.0 in Q4 2023.
• The 5-year median for Capital Expenditures is $1.7 million (2023), against an average of $2.2 million.
• The widest annual swing landed in 2023, when Capital Expenditures tumbled 89.56%; it then surged 141.54% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $9.1 million in 2022, then sank by 89.56% to $946000.0 in 2023, then soared by 141.54% to $2.3 million in 2024, then sank by 40.88% to $1.4 million in 2025, then fell by 18.87% to $1.1 million in 2026.
• The last three Capital Expenditures figures came in at $1.1 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.

Peer Comparison